GlobalData on MSN3mon
MSD’s CAPVAXIVE vaccine shows promise in pneumococcal disease trial
MSD’s CAPVAXIVE vaccine has demonstrated promising results from the STRIDE-8 Phase III trial, which showed positive immune ...
pharmaphorum23h
FDA says yes to MSD’s 21-valent adult pneumococcal jab
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...
Barron's7mon
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
FDA approval of Merck’s new pneumococcal vaccine, Capvaxive, tees up a new challenge to one of Pfizer’s most important products.
Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...